Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON24070
NL-OMON24070
Not Yet Recruiting
N/A

Research to (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism

Het Sint Lucas Andreas ziekenhuis0 sites114 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Het Sint Lucas Andreas ziekenhuis
Enrollment
114
Status
Not Yet Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

/A

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Het Sint Lucas Andreas ziekenhuis

Eligibility Criteria

Inclusion Criteria

  • •1\. Hemodialysis patients older than 18 years
  • •2\. Secondary hyperparathyroidism

Exclusion Criteria

  • •1\. Severe hypercalcemia (Ca2\+ \>2,65 mmol/L)
  • •2\. Severe liver failure

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not Yet Recruiting
N/A
Research to cost-effectiveness of paricalcitol of the treatment of secundary hyperparathyroidism at hemodialysis patients
NL-OMON24822Sint Lucas Andreas ziekenhuis114
Active, Not Recruiting
N/A
The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. - CEPSSecondary hyperparathyroidismMedDRA version: 9.1Level: LLTClassification code 10020708Term: Hyperparathyroidism secondary
EUCTR2007-006645-41-NLSint Lucas Andreas Hospital
Recruiting
Phase 4
The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.hyperparathyroidismincreased activity of the parathyroids1003394910029149
NL-OMON31628Sint Lucas Andreas Ziekenhuis114
Terminated
Phase 4
Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis SubjectsSecondary HyperparathyroidismDialysis
NCT00664430Abbott13
Active, Not Recruiting
N/A
Efficacy and safety of paricalcitol in the reduction of secondary hyperparathyroidism after kidney transplantation.Secondary hyperparathyroidism after renal transplantationMedDRA version: 16.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersTherapeutic area: Diseases [C] - Hormonal diseases [C19]
EUCTR2013-001326-25-ESFundación SENEFRO